Photons, protons or carbon ions for stage I non-small cell lung cancer – Results of the multicentric ROCOCO in silico study

• Published in: Radiotherapy and oncology Vol. 128; no. 1; pp. 139 - 146
• Main Authors: Wink, Krista C.J., Roelofs, Erik, Simone, Charles B., Dechambre, David, Santiago, Alina, van der Stoep, Judith, Dries, Wim, Smits, Julia, Avery, Stephen, Ammazzalorso, Filippo, Jansen, Nicolas, Jelen, Urszula, Solberg, Timothy, de Ruysscher, Dirk, Troost, Esther G.C.
• Format: Journal Article Web Resource
• Language: English
• Published: Ireland Elsevier B.V 01-07-2018; Elsevier BV
• Subjects: carbo-ions; compararive dosimetry; Hematology; Human health sciences; IMRT; In silico planning study; lung cancer; Multicentric trial; NSCLC; Oncologie; Oncology; Particle therapy; protons; Radiology, Nuclear Medicine and imaging; Radiotherapy; Sciences de la santé humaine; Stage I NSCLC; Stage I NSCLC Radiotherapy Particle therapy In silico planning study Multicentric trial; VMAT; Stage I NSCLC; Radiotherapy; In silico planning study; Particle therapy; Multicentric trial
• DOI: 10.1016/j.radonc.2018.02.024
• EISSN: 1879-0887
• ISSN: 0167-8140; 1879-0887

To compare dose to organs at risk (OARs) and dose-escalation possibility for 24 stage I non-small cell lung cancer (NSCLC) patients in a ROCOCO (Radiation Oncology Collaborative Comparison) trial.
For each patient, 3 photon plans [Intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and CyberKnife], a double scattered proton (DSP) and an intensity-modulated carbon-ion (IMIT) therapy plan were created. Dose prescription was 60 Gy (equivalent) in 8 fractions.
The mean dose and dose to 2% of the clinical target volume (CTV) were lower for protons and ions compared with IMRT (p < 0.01). Doses to the lungs, heart, and mediastinal structures were lowest with IMIT (p < 0.01), doses to the spinal cord were lowest with DSP (p < 0.01). VMAT and CyberKnife allowed for reduced doses to most OARs compared with IMRT. Dose escalation was possible for 8 patients. Generally, the mediastinum was the primary dose-limiting organ.
On average, the doses to the OARs were lowest using particles, with more homogenous CTV doses. Given the ability of VMAT and CyberKnife to limit doses to OARs compared with IMRT, the additional benefit of particles may only be clinically relevant in selected patients and thus should be carefully weighed for every individual patient.